The Fort Worth Press - First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak

USD -
AED 3.672507
AFN 65.000291
ALL 82.302472
AMD 357.809202
ANG 1.790403
AOA 917.999875
ARS 1549.753496
AUD 1.483019
AWG 1.8
AZN 1.695071
BAM 1.7757
BBD 2.012982
BDT 124.44505
BGN 1.77347
BHD 0.37742
BIF 3001.498025
BMD 1
BND 1.288366
BOB 11.659547
BRL 5.786199
BSD 0.99941
BTN 93.823002
BWP 13.990966
BYN 3.003223
BYR 19600
BZD 2.010077
CAD 1.43023
CDF 2314.999897
CHF 0.83989
CLF 0.025392
CLP 999.349858
CNY 6.67175
CNH 6.664955
COP 3317.97
CRC 445.37243
CUC 1
CUP 23.986201
CVE 100.108947
CZK 22.199349
DJF 177.719794
DKK 6.79576
DOP 60.748576
DZD 137.03898
EGP 53.677976
ERN 15
ETB 164.058597
EUR 0.90911
FJD 2.280097
FKP 0.756558
GBP 0.758415
GEL 2.590107
GGP 0.756558
GHS 11.709483
GIP 0.756558
GMD 73.99989
GNF 8855.599437
GTQ 7.63916
GYD 209.138162
HKD 7.846125
HNL 26.880632
HRK 6.831965
HTG 130.99394
HUF 331.400499
IDR 18258.7
ILS 3.24365
IMP 0.756558
INR 93.89715
IQD 1515.309712
IRR 1913737.499047
ISK 124.359748
JEP 0.756558
JMD 158.482001
JOD 0.709033
JPY 159.536496
KES 129.969693
KGS 87.449398
KHR 4098.364377
KMF 447.000415
KPW 900.00035
KRW 1335.549942
KWD 0.31161
KYD 0.833012
KZT 444.73296
LAK 22505.595075
LBP 89510.130151
LKR 332.650884
LRD 169.925324
LSL 16.93731
LTL 2.95274
LVL 0.60489
LYD 6.457851
MAD 9.963139
MDL 18.281771
MGA 4546.321093
MKD 55.927629
MMK 2099.568705
MNT 3604.028735
MOP 8.07799
MRU 40.587408
MUR 47.809734
MVR 15.398196
MWK 1733.209252
MXN 18.56698
MYR 4.093498
MZN 63.90174
NAD 16.93731
NGN 1345.220271
NIO 36.779626
NOK 9.64499
NPR 150.11644
NZD 1.81728
OMR 0.384499
PAB 0.999532
PEN 3.408766
PGK 4.563138
PHP 63.886011
PKR 276.374515
PLN 4.001925
PYG 6202.732761
QAR 3.653729
RON 4.860198
RSD 106.911017
RUB 82.600372
RWF 1476.632544
SAR 3.763042
SBD 8.097697
SCR 13.916252
SDG 601.493572
SEK 10.097505
SGD 1.289165
SHP 0.752984
SLE 23.05065
SLL 20969.503664
SOS 571.259959
SRD 37.4535
STD 20697.981008
STN 22.241387
SVC 8.745744
SYP 13002.000337
SZL 16.932226
THB 33.906
TJS 9.210795
TMT 3.5
TND 3.021631
TOP 2.40776
TRY 50.38997
TTD 6.787708
TWD 32.944402
TZS 2650.074057
UAH 45.435091
UGX 4147.791748
UYU 40.582868
UZS 12004.176313
VES 912.87925
VND 25764
VUV 120.719595
WST 2.810584
XAF 596.337034
XAG 0.021318
XAU 0.000260262813
XCD 2.70255
XCG 1.801394
XDR 0.707052
XOF 596.337034
XPF 108.275455
YER 236.550076
ZAR 16.993275
ZMK 9001.205356
ZMW 20.4664
ZWL 321.999592
SSP 5945.381189
MXV 2.083467
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak
First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak

First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak

The vaccine candidate is being evaluated in a ring vaccination trial as part of a comprehensive public health response

Text size:

NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / The first participants have been vaccinated with an investigational Ebola Sudan vaccine candidate provided by IAVI, a nonprofit scientific research organization, as part of a World Health Organization (WHO)-led ring vaccination trial taking place at Makerere University Lung Institute in Kampala. WHO prioritized evaluation of IAVI's candidate vaccine, which was already prepositioned in Uganda, as part of a global collaborative effort supporting the country's Ebola outbreak response.

This is Uganda's sixth outbreak of Ebola Sudan, which causes severe hemorrhagic fever disease with a case fatality rate of up to 50%. No licensed vaccines or therapeutics are available for Ebola Sudan, a Category A priority pathogen. Existing Ebola Zaire vaccines are not cross-protective for Ebola Sudan.

Mark Feinberg, M.D., Ph.D., IAVI president and CEO, said: "IAVI is grateful for the efforts that the WHO, the Ugandan government, and our public health partners in Uganda have made in enabling the rapid deployment of our investigational Ebola Sudan vaccine candidate to address the ongoing outbreak of Ebola Sudan in Uganda. We believe this clinical trial represents an important step toward evaluating the potential of IAVI's vaccine to protect exposed individuals from Ebola Sudan infection as well as demonstrating its value as a safe, effective, and accessible new tool to include in comprehensive outbreak responses in the future. Critically, having vaccine doses readily available in country made it possible for us all to mobilize in just days and to be able to incorporate evaluation of a promising Ebola Sudan vaccine clinical trial into the public health response very soon after the first reports of the current outbreak."

Uganda's current Ebola outbreak began on Jan. 30 with a confirmed infection in a health worker who died in Kampala, and since then 45 contacts have been identified. Close contacts are at elevated risk of infection and are prioritized for inclusion in a ring vaccination trial.

A study published recently in the New England Journal of Medicine confirms the high-level effectiveness of ring vaccination in containing Ebola outbreaks in the Democratic Republic of the Congo. The vaccine assessed in that study - ERVEBO®, Merck's single-dose Zaire ebolavirus vaccine - uses the same recombinant vesicular stomatitis virus (rVSV) viral vector platform as IAVI's Ebola Sudan vaccine candidate. ERVEBO® is licensed in more than a dozen countries.

More about IAVI's investigational Ebola Sudan vaccine candidate

In 2023, IAVI initiated a Phase 1 clinical trial of its rVSV-based Ebola Sudan vaccine candidate. The study was designed to evaluate the Ebola Sudan vaccine candidate in healthy U.S. adult volunteers at three dose levels. Initial results from that study indicate that the candidate vaccine was well tolerated across all three groups; immune responses were also detected in all three groups. These data were shared in November 2024 during the annual meeting American Society of Tropical Medicine and Hygiene. As a follow-up to this study, IAVI and our partners are currently planning a Phase 1 study in Africa.

In addition to being the backbone of the Ebola Sudan vaccine candidate, rVSV is the platform technology utilized in IAVI's portfolio of emerging infectious disease (EID) candidates, including a Lassa virus vaccine candidate currently in Phase 2 clinical trials in West Africa, supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European and Developing Countries Clinical Trials Partnership (EDCTP).

Rose Catlos
[email protected]
+12128471049

SOURCE: IAVI



View the original press release on ACCESS Newswire

J.Barnes--TFWP